CurrentCignaPolicy IP0739

Weight Loss - Glucagon-Like Peptide-1 Agonists BMI ≥ 35

Defines medical necessity and authorization criteria for coverage of Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide) for weight loss and certain FDA-approved non-weight-loss indications across Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyWeight Loss - Glucagon-Like Peptide-1 Agonists BMI ≥ 35

Policy CodePolicy IP0739

Change TypeCriteria updates and clarifications

Effective DateSep 15, 2025

Next Review Date

Key ActionObtain prior authorization and document that the patient meets the product- and indication-specific criteria, including baseline BMI, prior behavioral modification trial, diagnostic test results (e.g., sleep study/AHI for OSA), required comorbidities, and response thresholds.

SourceLink

POLICY UPDATE CHANGES

Policy authorizes coverage for non-weight-loss FDA-approved indications as applicable.

For Wegovy cardiovascular risk reduction initial therapy, the note clarifies that 'prior stroke' does not include transient ischemic attack (TIA).

Zepbound OSA initial therapy criterion modified: requirement for a sleep study remains but timeframe requirement (within past 1 year) was removed.

Conditions not recommended for approval clarified to specify 'concomitant use with other medications FDA-approved for weight loss' (previously unspecified).

Policy Statement and individual drug sections were updated to add phrasing 'with obesity or is overweight' and to align pediatric wording to 'with obesity'.

covered_with_criteriaCoverage stance

1Material changes in revision

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Authorization and Medical Necessity Criteria

Overall Policy Scope

GLP-1 and GLP-1/GIP agonists (Saxenda, Wegovy, Zepbound) are considered medically necessary when ONE of the following drug-specific branches (I, II, or III) is met.

ANY of the following

I. Saxenda authorization criteria (weight-loss indications and pediatric obesity). See Saxenda branch for detailed nested criteria.
II. Wegovy authorization criteria (weight-loss, pediatric obesity, and CV risk reduction). See Wegovy branch for detailed nested criteria.
III. Zepbound authorization criteria (weight-loss and obstructive sleep apnea indication). See Zepbound branch for detailed nested criteria.

Saxenda - Weight Loss in an Adult (FDA-Approved Indication)

Saxenda is medically necessary when ONE of the following is met (A Initial Therapy or B Continuing Therapy).

Saxenda - Pediatric Weight Loss (Ages 12 to <18)

Saxenda is medically necessary when ONE of the following is met (Initial or Continuing).

Wegovy - Weight Loss in an Adult (FDA-Approved Indication)

Wegovy is medically necessary when ONE of the following is met (Initial Therapy or Continuing Therapy).

Wegovy - Pediatric Weight Loss (Ages 12 to <18)

Wegovy is medically necessary when ONE of the following is met (Initial or Continuing).

Wegovy - Major Adverse Cardiovascular Event (MACE) Risk Reduction (Adults with established CVD)

Approve for 1 year when Initial or Continuing Therapy criteria are met.

Zepbound - Weight Loss in an Adult (FDA-Approved Indication)

Zepbound is medically necessary when ONE of the following is met (Initial Therapy or Continuing Therapy).

Zepbound - Obstructive Sleep Apnea (OSA), Moderate to Severe (Adults)

Approve for 1 year when Initial or Continuing Therapy criteria are met.

General Dosage and Co-administration Rules

Prescribing/dosing guidance and co-administration constraints applicable across products.

ALL of the following

Follow product-specific dose-escalation schedules and maintenance doses in prescribing information (Wegovy maintenance 2.4 mg QW recommended; Saxenda 3 mg QD maintenance; Zepbound maintenance 5, 10, or 15 mg QW with max 15 mg QW).
If dose escalation not tolerated, consider delaying escalation or reducing to prior tolerated dose per prescribing information.
None of the GLP-1 or GLP-1/GIP agonists are recommended to be coadministered with other GLP-1 or GLP-1/GIP agonists.

Conditions Not Covered (Not Medically Necessary)

Saxenda, Wegovy, and Zepbound are considered not medically necessary for any other use not specified in the authorization criteria, including but not limited to:

ALL of the following

Concomitant use with other medications FDA-approved for weight loss (e.g., phentermine, benzphetamine, diethylpropion, phendimetrazine, Contrave, phentermine/topiramate, orlistat) is not recommended/approved.
Concomitant use of GLP-1 agonists or GLP-1/GIP agonists with each other (including agents FDA-approved for type 2 diabetes) is not allowed.

Numeric Thresholds and Defined Terms

Response and Diagnostic Thresholds

Adult BMI class thresholdsClass 1: BMI ≥30 to <35 kg/m2; Class 2: BMI ≥35 to <40 kg/m2; Class 3: BMI ≥40 kg/m2

Saxenda response threshold (adults)≥ 4% reduction in baseline body weight at 16 weeks on therapy to continue beyond initial period

Wegovy response threshold (adults)≥ 5% reduction in baseline body weight at end of initial therapy to continue

Zepbound continuing-therapy weight-loss threshold≥ 5% reduction in baseline body weight for weight-loss continuation; for OSA continuation: ≥ 10% weight loss and stability in OSA signs/symptoms after ≥ 1 year of therapy

Pediatric BMI response threshold≥ 1% reduction in BMI from baseline for continuation in patients aged 12 to <18 years

OSA diagnostic threshold (AHI)

What Providers Must Do

Prior Authorization

Authorization required per criteria

Providers must obtain prior authorization and document that the patient meets the product- and indication-specific authorization criteria, including patient age, baseline BMI (baseline defined as prior to any GLP‑1 or GLP‑1/GIP agonist), trial of behavioral modification and dietary restriction, required comorbidities or diagnostic test results (e.g., sleep study/AHI for OSA), and required response thresholds for continuation.

No HCPCS/CPT/ICD codes are listed for this requirement.

Documentation Required

Document baseline and response measures

Include objective baseline and follow-up measures with authorization and continuation requests: record baseline BMI (prior to any GLP‑1/GLP‑1‑GIP agonist), documented weight change from that baseline, relevant weight‑related comorbidities, and diagnostic results for non‑weight indications.

Baseline BMI (defined as prior to any GLP‑1 or GLP‑1/GIP agonist)

Drug/Product References and Relevant Code Systems

NDC / Drug products referencedNDC|mixed

Saxenda	liraglutide subcutaneous injection (Novo Nordisk) - product referenced
Wegovy	semaglutide subcutaneous injection (Novo Nordisk) - product referenced
Zepbound	tirzepatide subcutaneous injection (Eli Lilly) - product referenced

Relevant clinical measurement codes (not listed explicitly in policy)ICD-10|CPT

No codes listed

Clinical and Indication Context

Saxenda, Wegovy, and Zepbound are members of the incretin class used for weight management. Saxenda and Wegovy are glucagon-like peptide-1 (GLP-1) receptor agonists; Zepbound is a dual-agonist with both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) activity. These agents are indicated as adjuncts to a reduced-calorie diet and increased physical activity to reduce excess body weight and help maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbidity; selected pediatric indications apply per product labeling (e.g., Saxenda for certain pediatric patients and Wegovy for patients ≥ 12 years of age).

Wegovy has an additional FDA-approved indication to reduce the risk of major adverse cardiovascular events (MACE) — defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — in adults with established cardiovascular disease who are obese or overweight; the policy’s authorization criteria for this indication require evidence of established CVD (for example, prior myocardial infarction, prior stroke — note: this does not include transient ischemic attack [TIA] — or symptomatic peripheral arterial disease) and that the drug will be used with optimized cardiovascular pharmacotherapy and lifestyle modification.

Zepbound is also FDA-indicated for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Authorization for the OSA indication requires documentation of a sleep study demonstrating a diagnosis of moderate to severe OSA with an apnea-hypopnea index (AHI) ≥ 15 events per hour, exclusion of predominately central sleep apnea/Cheyne-Stokes respiration, and concurrent use with behavioral modification and a reduced-calorie diet; continuation criteria for OSA include ≥ 1 year of therapy, ≥ 10% weight loss from baseline, and prescriber-documented stability in OSA signs or symptoms.

Operationally, the policy explicitly authorizes coverage for FDA-approved non–weight-loss indications as applicable (for example, Wegovy for CV risk reduction and Zepbound for OSA), and revision notes clarify certain points in those non-weight-loss branches (for example, clarifying that prior stroke does not include TIA and removing a 1-year timeframe requirement for the sleep study while retaining the sleep-study requirement).

Policy Changes and Effective Dates

2025-07-01added

New policy created (summary of changes noted as new policy).

2025-08-01clarified / revised

Policy authorizes coverage for non-weight-loss FDA-approved indications; Wegovy MACE risk-reduction criteria clarified that 'prior stroke' does not include transient ischemic attack (TIA); Zepbound OSA initial therapy requirement for a sleep study retained but the prior 1-year timeframe was removed; conditions not recommended for approval clarified to specify concomitant use with other medications FDA-approved for weight loss (examples updated).

2025-09-15revised (non-material)Latest